BioPharma Reporter reports AbbVie defence strategy for Humira

by , | Feb 18, 2020

On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab) competition in the US market. According to the BioPharma Reporter, AbbVIe CEO Gonzalez that explained AbbVie’s commercial US strategy will mimic the strategy employed in Europe and other markets, and stated that ex-US competition for adalimumab had been much more aggressive than AbbVie had predicted.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.

Our Latest News